Compare ENHA & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENHA | BWAY |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.1M | 547.7M |
| IPO Year | 2025 | 2011 |
| Metric | ENHA | BWAY |
|---|---|---|
| Price | $1.49 | $11.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.00 | ★ $19.27 |
| AVG Volume (30 Days) | ★ 821.4K | 95.7K |
| Earning Date | 11-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $32.42 |
| Revenue Next Year | $168.06 | $23.40 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.37 | $11.77 |
| 52 Week High | $4.60 | $26.63 |
| Indicator | ENHA | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 24.28 |
| Support Level | N/A | $11.90 |
| Resistance Level | $1.66 | $14.71 |
| Average True Range (ATR) | 0.10 | 0.57 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 44.63 | 7.58 |
Enhanced Group Inc develops and sells sports and performance-related products intended for use by athletes and consumers. Its offerings focus on products associated with physical performance, health, and recovery. Its two principal offerings include: (i) the Enhanced Games, a live, multi-sport competition platform designed to showcase both "Enhanced" and "Non-Enhanced" athletes pursuing world-record performances under medically supervised conditions; and (ii) Live Enhanced, a direct-to-consumer digital and clinician-guided wellness platform offering evidence-based protocols, supplements, and coaching for consumers seeking to improve health, longevity, and well-being. The majority of the company's revenue is derived from products associated with physical performance, health, and recovery.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.